KAHF Biotech, Inc.
Regulation Crowdfunding offering on Wefunder · Form C filed February 24, 2026 · Rochester, New York
KAHF Biotech, Inc., a Delaware corporation organized April 29, 2025 with offices in Rochester, New York, is developing antibody-based cancer therapeutics that target the KAHF receptor, with pancreatic ductal adenocarcinoma as its lead indication. The company is pre-revenue and preclinical, reports $0 in assets and revenue, and is offering SAFEs with a $50,000 target and a $124,000 maximum through Wefunder Portal LLC.
Profile details below were extracted automatically from the issuer's filing documents. Figures in the financial table come directly from the SEC's structured Form C data.
Offering terms
- Security
- Simple Agreement for Future Equity (SAFE)
- Maximum
- $124,000.00
- Price
- $1.00 per unit
- Pricing method
- Pro-rated portion of the total principal value of $50,000; interests will be sold in increments of $1; each investment is convertible to one share of stock as described under Item 13.
- Deadline
- July 29, 2026
- Oversubscriptions
- Accepted
- Intermediary
- Wefunder Portal LLC
Funding portal, SEC file 007-00033 - Intermediary fee
- 7.9% of the offering amount upon a successful fundraise, and be entitled to reimbursement for out-of-pocket third party expenses it pays or incurs on behalf of the Issuer in connection with the offering.
- Intermediary equity
- No
- Co-issuer
- KAHF Biotech I, a series of Wefunder SPV, LLC
Financials as filed
| Item | Most recent FY | Prior FY |
|---|---|---|
| Revenue | $0 | $0 |
| Cost of goods sold | $0 | $0 |
| Net income (loss) | $0 | $0 |
| Total assets | $0 | $0 |
| Cash and equivalents | $0 | $0 |
| Accounts receivable | $0 | $0 |
| Short-term debt | $0 | $0 |
| Long-term debt | $0 | $0 |
| Taxes paid | $0 | $0 |
Two fiscal years as reported on the Form C cover sheet. 1 employees. Offered in 56 states.
Use of proceeds
At the $50,000 target: 70% for therapeutic monoclonal antibody development and in vitro data development, 16.1% for legal, 7.9% Wefunder fee, and 6% for lab space and company trademark and tax. At the $124,000 maximum: the same percentages apply, with the minimum raise funding antibody development and provisional patent filings and the maximum raise funding preliminary in vitro and in vivo experiments.
Valuation
SAFE with a post-money valuation cap of $10,000,000 and an 80% discount rate (20% discount). Price per interest is $1.00, based on pro-rated portion of the $50,000 target. The offering price was set arbitrarily by the company without an independent appraisal or investment bank input.
Prior raises
Not stated
Financial statements
Financial statements for inception (April 29, 2025) to December 10, 2025 are labeled unaudited; the CEO certifies they are true and complete in all material respects. No independent CPA review or audit is stated.